These data suggest that sleep treatment improved neuropsychological symptoms and reduced blood Aβ42/40 ratio and Tau-pT181 protein levels in MCI patients due to Alzheimer’s disease. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.